Due to a growing interest in the occurrence of pharmaceutically active compounds (PhACs) and endocrine disrupting compounds (EDCs) in the aquatic environment and their potential impacts on humans and the environment, a collaborative study was conducted on these emerging contaminants in the effluents from the wastewater treatment plants (WWTPs) and in the drinking water supply system of Calgary, Alberta. A number of PhACs and EDCs were detected in the WWTP effluents, at concentrations ranging from ng/L to low µg/L. Although these compounds were generally removed from WWTP effluents during wastewater treatment, some compounds, such as carbamazepine were more persistent. Some target PhACs and EDCs were detected at low ng/L levels in the surface and potable water in this study. Currently, there is no evidence that trace amounts of PhACs and EDCs in Calgary's waterways can have a health impact on humans, but they may pose adverse chronic effects on aquatic life.
Introduction
Pharmaceutical drugs are chemicals used for diagnosis, treatment or prevention of disease, health condition or structure/function of the human body, as well as for similar veterinary uses (Daughton and Ternes 1999) . Over the past three decades, pharmaceutically active compounds (PhACs), including prescription and non-prescription drugs and their metabolites, have been detected in wastewater and the aquatic environment. In the mid1970s, clofibric acid (i.e., metabolite of the lipid regulator clofibrate), aspirin and caffeine were detected in wastewater (Hignite and Azarnoff 1977; Stumpf et al. 1999; Seiler et al. 1999) . A few years later, PhACs were detected in surface and ground water Daughton 2001) . In 1993, clofibric acid was detected in Berlin tap water (Heberer et al. 2001) . In recent years, there has been an increasing awareness of the occurrence of PhACs in the aquatic environment, due to the development of new, very sensitive analytical technologies (Petrovic et al. 2005; Richardson and Ternes 2005) . Concentrations of PhACs in the environment may increase in the future because of a rapid increase in the use of pharmaceuticals as a result of new chemical discoveries, and a growing and aging population.
Endocrine disrupting compounds (EDCs) are chemicals that interfere with the normal function of the endocrine system. EDCs are a structurally diverse group that includes natural and synthetic estrogens, alkyl phenols surfactants, phthalates, bisphenol A, brominated flame retardants and some pesticides. While the hypothesis that environmental chemicals may exhibit endocrine disrupting effects was first raised eighty years ago, this complex scientific issue was brought to the attention of the general public in the 1990s due to the connection between exposure to pollutants and effects on the endocrine system (Purdom et al. 1994; Daughton and Ternes 1999; Roefer et al. 2000; Trussell 2001; Birkett and Lester 2003; Sumpter and Johnson 2005; Mills and Chichester 2005; Falconer et al. 2006) .
PhACs and EDCs are released into the environment from urban, industrial and rural sources. An important source of these compounds is domestic sewage discharged from wastewater treatment plants (WWTPs) . It has been estimated that 30 to 90% of an administered dose of most antibiotics to humans and animals may be excreted from the body as active substances (HallingSørensen et al. 1998 ). The drugs used by humans and some EDCs (e.g., natural hormones) can be discharged into domestic sewer systems with urine/feces or by improper disposal. The drug residues and EDCs could reach the aquatic environment through incomplete removal during wastewater treatment processes, or by land application of biosolids and subsequent leaching or runoff (Halling-Sørensen et al. 1998; Jørgensen and Halling-Sørensen 2000; Weyer and Riley 2001) . Many veterinary drugs are present in manure, which can impact groundwater due to leaching or surface water due to runoff from agricultural fields (Jørgensen and Halling-Sørensen 2000) .
In an attempt to assess whether PhACs and EDCs are being released into the aquatic environment in the area of Calgary, Alberta, Canada, an investigation was conducted on the occurrence of selected classes of these compounds in WWTP effluents, and in the source water and treated drinking water for the city of Calgary. The objectives of the study were: (1) to obtain a better understanding of the extent to which these compounds are a risk to the environment and humans, and (2) depending on the monitoring results, develop a long-term mitigation plan for these emerging contaminants.
Materials and Methods

Sampling Sites
There are two WWTPs in Calgary; the Bonnybrook and Fish Creek WWTPs (Fig. 1) . The Bonnybrook WWTP is a tertiary treatment plant with biological phosphorus and nitrogen removal and ultraviolet (UV) disinfection, which serves a population of approximately 780,000. The Fish Creek WWTP is a tertiary treatment plant with chemical phosphorus removal and UV disinfection that serves only about 220,000 residents. The hydraulic retention time, a measure of the average length of time that a soluble compound remains in a constructed reactor, is longer in Bonnybrook compared to Fish Creek WWTP.
The City of Calgary operates two treatment plants for drinking water; the Bearspaw Water Treatment Plant (WTP) located on the Bow River and the Glenmore WTP located on the Elbow River (Fig. 1) . Both treatment plants employ pretreatment clarification, dualmedia filtration and chlorine disinfection.
Samples of WWTP effluents, surface water and drinking water were collected periodically from October 2002 to July 2004 for the analysis of PhACs and EDCs, and in vitro testing for estrogenic activity from October 2002. The sampling program for this study and the laboratories conducting the various types of analyses are summarized in Table 1 .
Analysis of PhACs
Volumes of 500 mL of WWTP final effluent, 1 L of surface water or 2 L of drinking water were extracted for the analysis of each class of PhACs using the methods developed by Metcalfe et al. (2003a,b) and Miao et al. (2002 Miao et al. ( , 2004 . All extractions were conducted using Oasis HLB solid phase extraction (SPE) cartridges (Waters, Mississauga, Ont.).
All of the glass bottles were pre-cleaned with solvent prior to sample collection. A method blank (distilled water) was extracted and analyzed with each batch of samples in the laboratory. Seven aliquots for each sample were used in the analysis of PhACs, four of which were spiked with calibration standards to develop a calibration curve using a standard additions protocol (Metcalfe et al. 2003a,b; Miao et al. 2002 Miao et al. , 2004 and the sample was analyzed in triplicate. The standard additions method was used for calibration to compensate for the effect of the sample matrix on the signal during analysis by liquid chromatography electrospray ionization tandem mass spectrometry.
Even though EnviroTest Laboratories was involved in the extraction of some samples in this study, this analytical services laboratory followed the procedure developed by Metcalfe et al. (2003a,b) and Miao et al. (2002 Miao et al. ( , 2004 for sample extractions. All analyses of extracts were conducted at Trent University using liquid chromatography tandem mass spectrometry (LC-MS/MS), as described by Metcalfe et al. (2003b) and Miao et al. (2004) . The method detection limits (MDLs) for each compound are listed in Table 2 .
Analysis of EDCs
Volumes of 12-L water samples or 4 L of WWTP final effluent were extracted for the analysis of EDCs. All samples were extracted at EnviroTest Laboratories by liquid-liquid extraction with chloroform, which was repeated twice. The organic phases were combined and filtered through glass frit funnels before concentrated to a final volume of 10 mL. The extracts were sent to the Institute of Ocean Sciences, where they were split quantitatively into three equal aliquots and analyzed for nonylphenol (NP), nonylphenol ethoxylayes (NPnEOs), phthalates and steroids.
The first aliquot was spiked with a representative suite of surrogate standards, processed through a number of cleanup steps and analyzed for NP and NPnEOs according to the LC-MS analytical methodology described by Shang et al. (1999) . The second aliquot was also spiked with a group of surrogate standards, processed through a number of cleanup steps and analyzed for phthalates according to the GC-MS method described by Lin et al. (2003) . To the third aliquot, surrogate standards including 180 ng of Ring-13 C6-NP and 500 ng of DnOP-d4 (Cambridge Isotope Laboratories Inc., Mass.) were added. The extracts were then filtered, concentrated, derivatized and analyzed for steroids by GC-MS according to the method developed by Ikonomou et al. (submitted for publication). All samples collected for the EDCs analyses were stored in pre-cleaned glass bottles. Two types of blank samples were analyzed in the laboratory. One blank sample was prepared and extracted by EnviroTest Laboratories. The other type of blank sample was prepared by the laboratory at the Institute of Ocean Sciences. All the results were blank-corrected. Surrogate standards were added prior to sample extraction in order to monitor extraction efficiency. The analytical results were corrected, based on the recovery of the surrogate standards.
Even though EnviroTest Laboratories was involved in the extraction of samples in this study, this laboratory followed the protocols developed by Shang et al. (1999) , Lin et al. (2003) and Ikonomou et al. (submitted for publication) for sample extraction. The instrumental analyses were performed at the Institute of Ocean Sciences.
Yeast Estrogen Screening (YES) Assay
The method for the YES assay was based on the work by Routledge and Sumpter (1996) . The method uses a recombinant strain of yeast in which the human estrogen receptor (hER) was integrated into the yeast genome upstream of a reporter gene, the lac-Z gene for expression of β-galactosidase. The hER is expressed in a form that binds with the estrogen response elements (ERE) within a hybrid promoter on the expression plasmid. Estrogen binds to hER and this ligand complex binds to the ERE elements on the hybrid promoter linked to the gene for β-galactosidase. The enzyme is synthesized and secreted into the medium and cleaves the substrate, chlorophenol red-β-D-galactopyranoside (CPRG), to produce a red colour from the normally yellow CPRG reagent.
For water samples, pre-conditioned Sep Pak C18 columns (Fisher Scientific, Canada) were used to extract EDCs from 1-L water samples followed by elution of the EDCs with 2 × 5 mL of methanol. Dechlorinated tap water (method blank) and 17β-estradiol-spiked samples were also extracted to determine the spike recovery efficiency, which was typically 80 to 100%. For turbid wastewater or biosolid sludge, samples were extracted by extraction into n-hexane (1:1 v/v) (Holbrook et al. 2001 ). All estrogenic responses were reported as µg estrogen equivalents (EE) relative to the response to the positive control, 17β-estradiol (E2).
The tests were conducted in 96-well microplates containing a standard curve with E2 and triplicate dilutions of each sample. The test was performed on 20 µL of solvent extracts of the original samples by allowing evaporation of the solvent before adding 200 µL of YES culture medium inoculated with a 16-to 20-h log-phase culture of yeast. All yeast cultures were checked for bacterial contamination by phase-contrast microscopy before testing. All tests were set up with negative (method blanks) and positive controls. The endpoints were estimated relative to induction of β-galactosidase activity in yeast exposed to E2 (positive control).
Plates were incubated at 30°C for 3 to 4 days. Endpoints were measured optically with a microplate reader. Turbidity was measured at a non-absorbing wavelength at 630 nm and β-galactosidase activity was measured at 540 nm, the wavelength for the maximum absorbance of phenol red. A standard curve was prepared and absorbance corrected for background turbidity. Corrected absorbance at 540 nm was then used in the standard curve to calculate the estrogen equivalent (EE) value.
Results and Discussions
PhACs in WWTP Effluents
As shown in Table 3 , some acidic and neutral PhACs were detected in the WWTP effluent samples, ranging from ng/L to µg/L. The concentrations of PhACs in the WWTP effluent can vary with the sampling time. According to Daughton (2001) , the overall effectiveness of removal of PhACs by WWTPs can fluctuate with time of day (both composition and volume of WWTP influent which are largely a function of daily population activity) and season (temperature, nutrient loads/physicochemical conditions). Thus WWTP effluent is not a homogenous material and a different sampling time may result in differences in drug content as seen in temporal variations in ammonia, BOD and pH, etc.
WWTPs were not specifically designed to remove PhACs. The elimination rate can vary from negligible to more than 99% (Ternes 1998) . Biodegradation and sorption could be involved in the elimination process for the drugs (Ternes 1998; Xia et al. 2005) . In addition, chemical degradation processes, such as hydrolysis and photolysis, can reduce the concentration of PhACs in wastewater (Velagaleti and Gill 2001) . As no samples of untreated wastewater (i.e., influent) were taken from the Calgary WWTPs in this study, results reported by Metcalfe et al. (2002) for the Calgary Bonnybrook WWTP and presented within aggregate Canadian data by Metcalfe et al. (2003a) were adapted to compare the relative concentrations of PhACs in wastewater before and after treatment (Fig. 2) . The data demonstrated that the concentrations of salicylic acid, ibuprofen and naproxen in the effluent were reduced significantly compared to the influent. Carbamazepine, however, was poorly removed from wastewater during treatment, which is consistent with other studies (Miao et al. 2005; Clara et al. 2004 ). This anti-epileptic drug has been detected in most WWTP effluents and, as a result, is a widely detected contaminant in receiving waters (Metcalfe et al. 2003b) . In this study, the concentration of carbamazepine in WWTP effluents was found to be within the range of 0.5 and 1 µg/L (Table 3) .
The levels of ibuprofen, naproxen, diclofenac and bezafibrate in Calgary's WWTP effluents (Table 3) were comparable to those from WWTPs in Finland (Lindqvist et al. 2005) , but the detection of PhACs showed a different pattern from those in the United States (Glassmeyer et al. 2005) . For instance, no ibuprofen or naproxen were detected by Glassmeyer et al. (2005) in their study. Compared to WWTP effluents across Canada, the levels of target acidic and neutral drugs in Calgary's WWTP effluents were generally similar to the median concentrations in Canadian WWTPs (Table 3) , except for ibuprofen and naproxen, which were present at concentrations substantially lower in Calgary's WWTP effluents. No clofibric acid or ketoprofen was detected in the effluents from Calgary WWTPs (Table 3) , which is consistent with other Canadian WWTP effluents (Metcalfe et al. 2003a ) but differs from WWTP effluents in Europe (Ternes 1998 ). The differences could be due to the variations in the removal rate of PhACs in wastewater treatment processes, or due to regional or seasonal differences in drug use patterns (Metcalfe et al. 2003a) .
Antibiotics in Bonnybrook and Fish Creek WWTP effluents were investigated as part of collaborative research on antibiotics from eight WWTPs in five cities across Canada and these data were previously reported by Miao et al. (2004) . Even though only low levels of antibiotics (<0.6 µg/L) were detected in Calgary's WWTP effluents, the results indicate that these compounds are not eliminated completely from wastewater during treatment (Table 4) . Among 19 target sulfonamide antibiotics, only four were detected (Table 4) , including sulfapyridine, sulfamethoxazole, sulfacetamide and sulfisoxazole, which are largely used for human medication. The sulfonamides mainly used for veterinary applications (sulfadiazine and sulfamethazine) were not found in Calgary's WWTP effluents. In addition, erythromycin (used for both humans and animals), tetracyclines (including doxycycline and tetracycline for livestock or aquaculture) and fluoroquinolones (ciprofloxacin, norfloxacin and ofloxacin mainly for humans) were also detected in the WWTP effluents (Miao et al. 2004 ). The concentrations of many antibiotics in Calgary's WWTP effluents were generally lower than or close to the median of the eight WWTP effluents, whereas the levels of fluoroquinolones were higher in Calgary's WWTP effluents, particularly in the Fish Creek WWTP effluent (Table 4) . (Metcalfe et al. 2003a ) (Ternes 1998 The relatively high levels of fluoroquinolones in Calgary's WWTP effluents may be attributed to the regional difference in the consumption of antibiotics, different sewage retention times and treatment technologies. The hydraulic retention time was 23 h for the Bonnybrook WWTP and 10 h for the Fish Creek WWTP at the time of sample collection. As the elimination of fluoroquinolines during wastewater treatment processes is mainly due to sorption onto sludge (Golet et al. 2003) , the differences in hydraulic retention time likely account for the higher levels of fluoroquinolones in the Fish Creek WWTP effluent relative to Bonnybrook.
PhACs in Surface Water
The PhACs detected in the upstream and downstream water (Table 5) were either lower or comparable to those reported by Ternes (1998) , Kolpin et al. (2002) , Metcalfe et al. (2003b) , Lindqvist et al. (2005) , Glassmeyer et al. (2005) and Batt et al. (2006) . The differences could be related to the various factors, such as population, regional differences in drug use pattern, WWTP removal efficiency, the capacity and flow of receiving water, or the selection of sampling sites.
For the upstream Bow River (i.e., source water) from Calgary, ibuprofen, pentoxifylline, cyclophosphamide, carbamazepine, caffeine, cotinine and sulfamethoxazole were detected at concentrations less than 0.2 µg/L ( Table 5 ). These PhACs are used for human medication or used as stimulants (i.e., caffeine) or are present as metabolites of nicotine (i.e., cotinine) (e.g., Seiler et al. 1999 ). The drug residues in surface water could be resulting from the discharge of WWTP effluents from the small residential communities located upstream of Calgary. As indicated previously, carbamazepine was poorly removed during sewage treatment processes, and thus, ubiquitous in the aquatic environment (Ternes 1998) . Similarly, cyclophosphamide is not readily eliminated in WWTPs (Kümmerer et al. 2000) , and thus, is probably present in the Bow River as a result of discharges of final effluent.
For the upstream sample from the Elbow River (i.e., source water), caffeine, cotinine and fluoroquinolones were detected in the sample (Table 5 ). The presence of these PhACs indicated that there have been human inputs. While there are no WWTPs upstream of the Elbow River, it is possible that PhACs enter the aquatic environment via other pathways, such as improper disposal and/or private septic systems. More work is needed to determine whether there is a point-source contamination upstream.
Compared to the upstream surface water, several more PhACs were detected in the downstream Bow River (Table 5 ), but the levels of target PhACs in the downstream surface water were all below 0.1 µg/L after Standard deviations (n = 3) given in parentheses.
c dilution in the river. In comparison with the final effluents from Bonnybrook and Fish Creek WWTPs, fluoroquinolines and cyclophosphamide seemed to be depleted in the downstream surface water, although the variation may simply be a reflection of different loadings of PhACs in the sewage. Some PhACs have long environmental half-lives and tend to be persistent in the aquatic environment (Ternes 1998; Ongerth and Khan 2004; Hernando et al. 2006) . Most drugs are designed to target specific metabolic pathways in humans and animals, but they could have potential impacts on non-target organisms, such as affecting normal development and reproduction, developing resistance to antibiotics, and influencing oxidative metabolism in liver cells and leading to oxidative damage (Weyer and Riley 2001; Flaherty and Dodson 2005; Gagné et al. 2006; Hernando et al. 2006) . Certain PhACs potentially have cumulative and synergistic effects when combined with other PhACs (Jørgensen and Halling-Sørensen 2000; McBride and Wyckoff 2002; Daughton 2002; Flaherty and Dodson 2005) . Some PhACs may bioaccumulate and induce effects in the aquatic environment (Halling-Sørensen et al. 1998; Robinson et al. 2005) . Moreover, some PhACs may partition into sediments, which could increase the environmental exposure for aquatic life (Löffler et al. 2005; Oetken et al. 2005) . Even though very little is known about long-term effects of PhACs to aquatic organisms, chronic sublethal effects, rather than acute toxic effects are expected (Ternes 1998; Fent et al. 2006; Carlsson et al. 2006; Jjemba 2006 ).
PhACs in Drinking Water
A number of studies have indicated that pharmaceuticals may not be eliminated by conventional treatment processes and thus enter into potable water (Stackelberg et al. 2004; Snyder et al. 2005; Loraine and Pettigrove 2006) . Several target PhACs, including carbamazepine, caffeine, cotinine, clofibric acid, ofloxacin and sulfamethoxazole were detected at low ng/L concentrations in Calgary's drinking water (Table 6) . At this stage, it remains unknown why clofibric acid was only detected in the finished drinking water samples collected in 2004, but not in the source water. In addition, the level of carbamazepine (0.135 µg/L) in the grab sample taken from Bearspaw WTP in 2003 was higher in drinking water than in the grab sample of upstream surface water (0.043 µg/L). The variation could be related to differences in water flow, drug use pattern or the representative of the grab sample. Further investigations are required in order to obtain a clear picture for the occurrence of PhACs in drinking water. Even though PhACs were detected in the drinking water samples, the quantities of these compounds were several magnitudes lower than those applied in medication (i.e., therapeutic dosage). Higher exposure to PhACs for humans is probably through medications, dermal absorption of topical medications and inhalation (Snyder et al. 2005) . It has been suggested that low levels of PhACs could have a potential adverse effect on aquatic organisms (e.g., Ternes 1998; Fent et al. 2006; Carlsson et al. 2006; Jjemba 2006) , whereas no research to date has identified a risk to human health for people to drink water containing trace levels of PhACs (Webb et al. 2003; Snyder et al. 2005) . Nevertheless, antibiotic residues are suspected to induce resistances in bacterial strains which could potentially have an adverse impact on public health (Hirsch et al. 1999) . Pomati et al. (2006) reported that a mixture of pharmaceuticals at environmental exposure levels inhibited the growth of human embryonic cells by affecting their physiology and morphology. More research is necessary in order to understand the effects of long-term and low-level exposure to complex mixtures of PhACs.
EDCs in WWTP Effluents
The results for EDCs in the WWTP effluents are given in Tables 7 and 8 . The concentrations of steroid estrogens in the WWTP effluents were less than 0.01 µg/L, which were close to or lower than the levels reported by Ternes et al. (1999) and Servos et al. (2005) . In both of the WWTP effluents, testosterone, 17α-estradiol, equilin, mestranol, equilenin and 19-norethindrone were below the detection levels.
The principal mechanisms for removal of steroid estrogens are likely to be sorption and biodegradation Standard deviation (n = 3) given in parentheses. (Johnson and Sumpter 2001) . Baronti et al. (2000) assessed six WWTPs around the City of Rome and found an average 87% removal of 17β-estradiol (E2), 61% of estrone (E1), 85% of 17α-ethinylestradiol (EE2) and 95% of estriol (E3) by activated sludge treatment.
Removal efficiencies for NP and NPnEO in a full-scale WWTP exceeded 90% (Esperanza et al. 2004) . The high partitioning coefficient of NP suggested that they adsorb to particulate matter and are concentrated in biosolids (Holbrook et al. 2001) . Rapid removal of E2, E1 and estrogenicity when exposed to sewage slurries was confirmed by laboratory aerobic reactor experiments (Servos et al. 2005) .
As indicated previously, the characteristics of WWTP effluents can vary with type and quantity of influent, the sewage retention time and treatment technology (Metcalfe et al. 2003a) . Differences in treatment technology deployed in WWTPs and in sewage retention time could, in part, result in different removal rates for EDCs as seen in the case of PhACs. For example, E2, E1 and E3 were below the method detection limit in the sample from Fish Creek WWTP effluent, whereas EE2 was not found in the Bonnybrook effluent. In addition, there were sharp differences between the two WWTP effluents in the levels of NP, phthalates and NPnEO.
The YES assay, a specific and sensitive method for assessing chemical interaction with the estrogen receptor (Gaido et al. 1997) , was used in this study to assess estrogen activity. WWTP influent, effluents from different treatment stages and sludge were taken from Bonnybrook WWTP for the YES assay. Similar to the observation made by Holbrook et al. (2001) , WWTP influent and primary effluent did not exhibit appreciable estrogenic activity compared to the final effluent. This was probably due to the sample/solvent volume ratio used in extraction and/or anti-estrogenic activity of complex samples (Shappell 2006) . Nonetheless, our results confirmed that EDCs are enriched in biosolids during the sewage treatment processes through sorption. The estrogen equivalent was 0.2 µg/kg total solids in sludge and 36 µg/kg total solids in digested sludge, respectively. The higher response in estrogenic activity observed in the digested sludge could be due to cleavage of the conjugates of steroid estrogens in the digester, desorption of EDCs in the digestion process, and transformation from E1 to E2 as E2 has a much higher estrogenic activity than E1 (Joss et al. 2004 ).
EDCs in Surface Water and Drinking Water
Steroid estrogens were detected neither in the upstream surface water (source water) nor in the downstream surface water of Calgary, including estrone, equilin, 17α-estradiol, testosterone, 17β-estradiol, equilenin, mestranol, 19-norethindrone, 17α-ethinylestradiol and estriol. These results were different from those reported by Kolpin et al. (2002) , which is probably due to their biased selection of sampling sites. Even though steroid estrogens in sewage cannot be entirely removed by WWTPs, they are diluted in receiving water and may even be eliminated through sorption onto suspended solids, accumulation in animal tissue (particularly in body fat) and/or biodegradation (Birkett and Lester 2003; Hanselman et al. 2003; Falconer et al. 2006) . Alkylphenols (such as NP) and NPnEO have been frequently detected in surface water in the lower µg/L range (Table 9) . Alkylphenols (such as NP) and NPnEO are relatively persistent in surface water, and they also show a strong tendency to bind to solids or sediments, resulting in a significant reservoir in the aquatic environment (Johnson and Sumpter 2001; Wenzel et al. 2004) . These compounds are known to be toxic to aquatic life and exhibit estrogenic activity at concentrations of a few µg/L (Wenzel et al. 2004) . Synergistic effects may need to be considered due to the presence of the mixture of EDCs in the environment (Falconer et al. 2006) . With reference to phthalate plasticizers, Canadian freshwater guidelines are available for only two phthalates; bis(2-ethylhexyl) phthalate (16 µg/L) and di-n-butyl phthalate (19 µg/L). The concentrations of the phthalates in the surface water from the Calgary area were far below these guidelines ( Table 9 ).
The YES assay was used to assess the estrogenic activity in the upstream surface water (i.e., source water). The results from a quarterly monitoring program indicated a low level of estrogenic activity in the surface water in 2003 and early 2004 (Table 10 ). The estrogenic activity could be introduced by estrogen-mimicking compounds in the water and may have potential impacts on aquatic life.
In the finished drinking water from Calgary's WTPs, no steroid estrogens were detected, but NPnEO, NP, bisphenol A and phthalates were present (Table 9) . Regarding estrogenic activity, the YES assay did not show any confirmatory positive response above the detection limit (Table 10) . Currently, there is no evidence to show that there are human health risks associated with exposure to the levels of estrogens and other EDCs found in Calgary's drinking water. However, more research is necessary and further monitoring is currently underway.
Summary
A collaborative study was conducted on the occurrence of PhACs and EDCs in WWTP effluents, drinking water and in the waterways of Calgary. Some of the target PhACs and EDCs were detected in the WWTP effluents and in the drinking water supply system of Calgary, with the concentration ranging from ng/L to µg/L. Currently there is no Canadian drinking water guideline or Canadian freshwater guideline established for PhACs and many EDCs, even though California has proposed language for monitoring the occurrence of drugs in water intended for groundwater recharge. Based on this study, it is unlikely that there is an immediate health concern for humans as no evidence has been found between human health and exposure to the levels of PhACs/EDCs detected in the potable water from Calgary. Nevertheless, PhACs and EDCs in the environment might have potential adverse effects on aquatic life. 
